Eli Lilly & Co. (NYSE: LLY) has announced that it has received market approval from the US Food and Drug Administration (FDA) for Ebglyss (lebrikizumab), a new treatment for adults and children aged 12 years and over suffering from moderate-to-severe atopic dermatitis (AD). Ebglyss is an interleukin-13 (IL-13) inhibitor that targets the IL-13 cytokine, overlapping with the binding site of the IL-4Rα subunit of the IL-13Rα1/IL-4Rα heterodimer, effectively inhibiting IL-13 signaling. This mechanism is similar to that of Sanofi’s Dupixent (dupalimab), yet Ebglyss offers a more convenient once-per-month dosage schedule, as opposed to Dupixent’s twice-a-month administration.
Lebrikizumab, originally developed by US biotech Dermira, was acquired by Lilly for USD 1.1 billion in 2020. Prior to this acquisition, Spain’s Almirall S.A. had licensed exclusive rights to develop lebrikizumab in Europe in 2019 and continues to hold control in those territories. Ebglyss first gained approval in Europe in 2023 and expanded its market presence to Japan earlier this year. – Flcube.com
